https://kstockbriefing.com
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to acquire 592,769 common treasury shares directly on the open market (valued at approx. KRW 100.0B) to stabilize its share price and enhance shareholder value. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Treasury Share…
![[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Host / 2025-09-10](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환알테오젠.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will participate in the presentation session at ‘Hankyung Korea Investment Week 2025’ held at the Conrad Seoul Hotel in Yeouido to present its bio-platform technologies and pipeline status/plans to domestic and international investors and the media. 📊 [Key Disclosure Details & Major Figures Summary] 📝…
Read More “[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Host / 2025-09-10” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed the signing of a pharmaceutical contract manufacturing agreement with a US-based pharmaceutical company valued at approx. KRW 1.800 trillion (USD 1,294,637,000), representing 39.59% of its FY2024 consolidated revenue. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has voluntarily disclosed the publication and website submission of its ‘Samsung Biologics ESG Report 2025’, detailing its economic, social, and environmental achievements for FY2024. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verifying Detailed ESG Performance via Published…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has received final Part 2 approval from the European Medicines Agency (EMA) for its Phase 3 Clinical Trial Application (CTA) for ‘CT-P44’, a biosimilar candidate to Darzalex, allowing clinical site initiation and patient enrollment in Europe. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion issued a re-disclosure regarding media reports on its planned KRW 300.0B plant investment in Yesan, South Chungcheong Province, stating that a Memorandum of Agreement (MOA) for a drug product (DP) facility was signed in February and details remain under discussion. 📊 [Key Disclosure Details &…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has voluntarily disclosed the signing of a pharmaceutical contract manufacturing agreement with a European pharmaceutical company valued at approx. KRW 88.4B (USD 63,786,500). 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Contract Execution and Subsequent Official Disclosures…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a corrected filing for its corporate spin-off decision originally disclosed on May 22, 2025, updating the English name of the newly established entity and postponing the overall spin-off schedule—including the EGM date (Oct 17), spin-off date (Nov 1), trading suspension period, and…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued a corrected investor caution notice disclosing that, in accordance with the revised corporate spin-off schedule (August 22, 2025), the adjusted final trading day for its stock futures/options has been postponed to October 29, 2025, and the non-listing date for new contract months…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is additionally listing 18,812 common shares on August 14, 2025, following the exercise of stock options by employees. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Additional Listing Execution on Scheduled Date (August 14, 2025) This disclosure…